Abstract:ABSTRACT The liver has a remarkable capacity to regenerate and thus compensates for repeated injuries through toxic chemicals, drugs, alcohol or malnutrition for decades. However, largely unknown is how and when alterations in the liver occur due to tolerable damaging insults. To that end, we induced repeated liver injuries over ten weeks in a mouse model injecting carbon tetrachloride (CCl 4 ) twice a week. We lost 10% of the study animals within the first six weeks, which was accompanied by a steady deposition of extracellular matrix (ECM) regardless of metabolic activity of the liver. From week six onwards, all mice survived, and in these mice ECM deposition was rather reduced, suggesting ECM remodeling as a liver response contributing to better coping with repeated injuries. The data of time-resolved paired transcriptome and proteome profiling of 18 mice was subjected to multi-level network inference, using Knowledge guided Multi-Omics Network inference (KiMONo), identified multi-level key markers exclusively associated with the injury-tolerant liver response. Interestingly, pathways of cancer and inflammation were lighting up and were validated using independent data sets compiled of 1034 samples from publicly available human cohorts. A yet undescribed link to lipid metabolism in this damage-tolerant phase was identified. Immunostaining revealed an unexpected accumulation of small lipid droplets (microvesicular steatosis) in parallel to a recovery of catabolic processes of the liver to pre-injury levels. Further, mild inflammation was experimentally validated. Taken together, we identified week six as a critical time point to switch the liver response program from an acute response that fosters ECM accumulation to a tolerant “survival” phase with pronounced deposition of small lipid droplets in hepatocytes potentially protecting against the repetitive injury with toxic chemicals. Our data suggest that microsteatosis formation plus a mild inflammatory state represent biomarkers and probably functional liver requirements to resist chronic damage. Graphical abstract The datasets generated via transcriptomics, proteomics as well as blood, histopathological and biochemical analysis were analyzed in an independent and integrative manner. The independent analysis was performed via state-of-the-art statistical approaches i.e. differential and consistently regulated genes and proteins. Combining the results identified three fibrosis phases. Using the KiMONo algorithm, a fibrosis specific multi-omic network was inferred. Within this network we identified several nodes connecting phase III specific features forming 13 distinct multi-omic modules suggesting a tolerance scheme. Some of these modules were experimentally validated and compared to 11 independent human studies of various liver diseases.

Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Dissecting compounded hepatocyte injury in a model of MASLD progression from human induced pluripotent stem cells

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Myeloid‐Mas Signaling Modulates Pathogenic Crosstalk among MYC+CD63+ Endothelial Cells, MMP12+ Macrophages, and Monocytes in Acetaminophen‐Induced Liver Injury

Repeated Toxic Injuries of Murine Liver Are Tolerated Through Microsteatosis and Mild Inflammation

Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions

Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease

Hydrogel Microfluidic‐based Liver‐on‐a‐chip: Mimicking the Mass Transfer and Structural Features of Liver

Hepatocyte-specific Mas Activation Enhances Lipophagy and Fatty Acid Oxidation to Protect Against Acetaminophen-Induced Hepatotoxicity in Mice

Tolerance of Repeated Toxic Injuries of Murine Livers is Associated with Steatosis and Inflammation

A pumpless liver-on-a-chip for drug hepatotoxicity analysis

Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy

The LIDPAD Mouse Model Captures the Multisystem Interactions and Extrahepatic Complications in MASLD (Adv. Sci. 35/2024)

A High-Throughput Microphysiological Liver Chip System to Model Direct and Idiosyncratic Drug-Induced Liver Injury Using Human Liver Organoids

Modeling Metabolic-Associated Steatohepatitis with Human Pluripotent Stem Cell-Derived Liver Organoids

A metabolic-dysfunction associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system

Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply

Spatially resolved rewiring of mitochondria-lipid droplet interactions in hepatic lipid homeostasis.

Ex Vivo Tools and Models in MASLD Research